Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 10/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554231 | 0.73 | ACE (0.41) | P2RX7 | |
| SCHEMBL3710388 | 0.71 | LMNA (0.53) | POLQPKMLMNAFASN | |
| SCHEMBL31611107 | 0.69 | CCR3 (0.42) | POLQPKMP2RX7 | |
| SCHEMBL9001880 | 0.68 | HTT (0.59) | PKMTSHRLMNAFASN | |
| SCHEMBL1522068 | 0.68 | HTT (0.59) | PKMTSHRLMNAFASN | |
| SCHEMBL2312935 | 0.68 | LMNA (0.49) | PKMLMNAFASN | |
| SCHEMBL9001877 | 0.67 | PKM (0.58) | PKMLMNAFASNALDH1A1 | |
| SCHEMBL24230531 | 0.66 | UCHL1 (0.46) | PKMLMNA | |
| SCHEMBL13350264 | 0.66 | PKM (0.49) | PKMLMNAFASN | |
| SCHEMBL17213398 | 0.66 | PKM (0.49) | PKMLMNAFASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718693-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| US-20100113443-A1 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | WYETH (US) | 2010-05-06 | — | — | US | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | POLQ 3870/4885PKM 1373/4885ALOX15 331/4885 |
| US-20100113443-A1 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS | PLA2G4B, PLA2G4A, PLA2G1B | POLQ 3124/4885PKM 1704/4885ALOX15 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.